Skip to main content
Premium Trial:

Request an Annual Quote

OGT Acquires Sense Proteomic

NEW YORK (GenomeWeb News) – Oxford Gene Technology has acquired protein array firm Sense Proteomic for an undisclosed sum.

UK-based Sense Proteomic has identified biomarker panels for a variety of diseases including prostate cancer and lupus. According to OGT, Sense Proteomic's technology can identify a stage of disease by monitoring changes in autoantibody production during disease progression and also can be used to monitor response to therapeutic interventions.

"This deal, combined with our recent development of an ultra high throughput DNA microarray facility, gives OGT a unique blend of genomic and proteomic technologies and will lead to the development of biomarkers with profound clinical significance," OGT CEO Mike Evans said in a statement.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.